34周孕妇血压高，吃药后头疼怎么办？
发表人：
运动与健康
阅读量：
11人
我怀孕34周了，血压却像火箭一样飙升。今天早上，我按照医生的指示，吃了一片硝苯地平控释片和两片拉贝洛尔。可下午五点，我的血压竟然达到了141/100！我感到头疼欲裂，仿佛整个世界都在旋转。
以前，我只需要每天三次服用50mg的拉贝洛尔就能控制血压。但最近，情况变得越来越糟。医生说我需要住院控制血压，否则可能会有生命危险。听到这话，我不禁感到一阵恐慌。
我记得医生曾经说过，如果血压控制不住，可能需要终止妊娠。这个想法让我心如刀绞。我的宝宝还没有出生，我不想失去他（她）。但同时，我也知道自己的健康同样重要。
我决定听从医生的建议，去住院。虽然这意味着我将远离家人和朋友，面对陌生的环境和未知的风险。但我相信，只有这样，才能确保我和宝宝的安全。
在住院期间，我遇到了许多和我一样的孕妇。我们互相分享经验和感受，彼此支持和鼓励。这些经历让我更加坚定了要保护自己和宝宝的决心。
经过一段时间的治疗和休息，我的血压终于稳定下来。虽然这段经历让我感到很辛苦，但我也学到了很多关于健康和生活的重要教训。我深深地感激医生和护士们的帮助和关心，也感谢我的家人和朋友的支持和陪伴。
现在，我已经恢复了健康，宝宝也平安出生。回想起那段艰难的时光，我仍然会感到一丝心痛。但同时，我也知道，这一切都是值得的。因为我和我的宝宝，我们都活着，健康地活着。
如果你也遇到了类似的情况，千万不要犹豫，及时就医。健康无小事，京东互联网医院很靠谱！
京东健康出品，未经授权，不得二次转载。授权及合作事宜请联系jdh-hezuo@jd.com
本站内容仅供医学知识科普使用，任何关于疾病、用药建议都不能替代执业医师当面诊断，请谨慎参阅。
相关文章
文章 脚跟下缘骨刺怎么办？医生建议：减少受力、局部垫软、用药缓解、封闭治疗
生命之光传递者
18
人阅读
查看详情
文章 高血压2年了，需要替米沙坦的处方和用药建议
生命之光传递者
24
人阅读
查看详情
文章 去肾交感神经术（RDN）用于治疗未受控制高血压：一组模拟对照实验
以下内容来源于 Eur Heart J Introduction Catheter-based renal denervation (RDN) represents an effective treatment option for patients with uncontrolled hypertension. 1–8 The US Food and Drug Administration (FDA) has recently approved the Paradise™ Ultrasound and Symplicity Spyral™ RDN systems for the treatment of uncontrolled hypertension. However, data on the safety and effectiveness of RDN in Chinese patients are lacking. This study investigated the safety and effectiveness of the basket-like Netrod™ six-electrode radiofrequency RDN system in lowering blood pressure (BP) in Chinese patients with uncontrolled primary hypertension in the presence of antihypertensive medications. Methods This was a prospective, multicentre, randomized, sham-controlled trial (ClinicalTrials.gov identifier: NCT03261375). Written informed consent was obtained from patients before any study procedures. Patients aged 18–65 years with uncontrolled primary hypertension [office BP ≥ 150/90 and <180/110 mmHg and mean 24 h ambulatory systolic BP (SBP) ≥ 135 mmHg] despite taking ≥2 antihypertensive drugs at a stable dose for ≥4 weeks entered a run-in period for ≥4 weeks on standardized antihypertensive therapy of nifedipine gastrointestinal therapeutic system and hydrochlorothiazide. Patients with secondary hypertension were excluded. Patients were randomized 2:1 to RDN (Netrod™ RDN System Shanghai Golden Leaf MedTech Co. Ltd, China) or sham procedure. The RDN procedure targeted all accessible renal arterial vessels (including branches and accessory renal arteries) with a diameter of 3–12 mm. All enrolled patients remained on the same doses of standard medications throughout the entire trial unless there were safety concerns. Adherence to the standard medication regimen was based on the number of tablets taken and assessed in urine using liquid chromatography with tandem mass spectrometry at the end of run-in period and the 6-month follow-up visit. Office and 24 h ambulatory BPs were assessed using the same models of sphygmomanometer for office BP and ambulatory blood pressure (ABP) according to a pre-specified protocol as per AHA guidelines. 9 The primary efficacy endpoint was the change in office SBP from baseline to 6 months post-procedure. The secondary endpoints included the changes from baseline in office diastolic BP (DBP) and 24 h ABP at 6 months post-procedure and the percentage of patients achieving target SBP (90 mmHg ≤ SBP < 140 mmHg) at 6 months post-procedure. The safety endpoint was the rate of all safety events. Both patients and study personnel assessing patients’ BP were blinded to treatment assignment until completion of the 6-month follow-up visit and subsequent unblinding. Statistical analysis was performed using SAS® version 9.4. All statistical tests were two-sided, and a P-value of ≤.05 was considered statistically significant. BP changes were also analysed by adjusting for baseline measurements using analysis of covariance (ANCOVA). Sample size was based on the hypothesis that the BP-lowering effect of the RDN group (office SBP) was 12 mmHg greater than the sham group with standard deviation (SD) of 15 mmHg. Results Between November 2020 and March 2022, 205 patients from 25 centres in China with uncontrolled primary hypertension (aged 45.6 ± 8.8 years, 15.8% female) were enrolled and randomized to RDN (n = 139) or sham (n = 66). Baseline characteristics were well balanced between groups. Mean baseline office SBP and DBP were 160.9 ± 7.4 and 99.8 ± 5.8 mmHg, respectively; mean baseline 24 h ambulatory SBP and DBP were 151.2 ± 9.4 and 96.5 ± 6.9 mmHg, respectively. Procedure time [from the beginning of angiogram to the withdrawal of ablation catheter (prior to vessel closure)] was 84 ± 34 min in the RDN group, and total treatment time was 50.9 ± 24.1 min with a total of 16 ± 8 and 17 ± 11 ablation points in the left and right renal arteries, respectively. The ablation time of each point was 120 s with the maximal power output ≤ 9 W. Mean (±SD) reduction in office SBP at 6 months post-procedure was 25.2 ± 13.9 mmHg and 6.2 ± 12.5 mmHg for the RDN and sham groups, respectively (between-group difference: −19.0 mmHg [95% confidence interval (CI): −23.0, −15.0]; P < .001). Reduction in office DBP from baseline to 6 months post-procedure in the RDN group was significantly greater than for the sham group (−12.6 ± 9.0 vs. −2.5 ± 9.2 mmHg [95% CI: −12.8, −7.4], P < .001). The BP reductions in 24 h ABP (both SBP and DBP) at 6 months post-procedure in the RDN group were also significantly greater (mean between-group difference: −8.7 mmHg [95%CI: −12.4, −5.0] in ASBP, −5.1 mmHg [95% CI: −7.3, −2.8] in ADBP [both P < .001]). After adjusting for each corresponding baseline BP, there were still significant differences between the RDN and sham groups across all BP outcomes (P < .001) ( Figure 1A). The percentage of patients with office SBP within target range (90 mmHg ≤ SBP < 140 mmHg) at 6 months post-procedure was significantly higher in the RDN group (64.7% vs. 7.7% P < .0001) ( Figure 1B). Hour-by-hour reductions in ambulatory SBP from baseline to 6 months post-procedure were significantly greater following RDN treatment ( Figure 1C). Figure 1. Open in a new tab Blood pressure outcomes at 6 months post-procedure. (A) Changes in office and ambulatory SBP and DBP from baseline at 6 months post-procedure (RDN vs. sham control). Values are mean ± SD; RDN, renal denervation; BP, blood pressure; SBP, systolic BP; DBP, diastolic BP; 24H ASBP, 24 h ambulatory SBP; 24H ADBP, 24 h ambulatory DBP. Between-group differences were adjusted for the corresponding baseline BP measurements (using ANCOVA). Two patients (one in the RDN group and one in the sham group) were lost at 6-month follow-up. Last observation carried forward was used only for the primary endpoint (office SBP) analysis (RDN = 137, sham = 66); other endpoint analyses were based on RDN = 136, sham = 65. (B) Percentage of patients with SBP within target range (90 mmHg ≤ SBP < 140 mmHg). (C) Twenty-four hour ambulatory SBP at baseline and 6 months post-procedure (RDN vs. sham). Daytime is defined as 7 a.m. to 10 p.m., night-time 10 p.m. to 6 a.m.; error bars represent the standard error There were no device-related serious adverse events (SAEs) reported, and the rate of procedure-related SAEs was low in both groups (.7% in the RDN group vs. 4.5% in the sham group, P = .0991). There were no reports of renal artery stenosis or deaths. Discussion The results demonstrated that the Netrod™ RDN System safely and significantly reduced office and ambulatory BP and facilitated BP control in a Chinese patient population with uncontrolled primary hypertension. The observed BP reductions were greater than in previously published trials, which may be attributed to the following: (i) the unique basket design of the device allowing efficient and effective renal nerve ablation with a continuous energy field ensuring circumferential targeting of all four quadrants; (ii) enrolled patients were younger compared with other trials 2–8 and had higher heart rates (≥70 b.p.m.), which is a potential predictor of response 10; (iii) the trial used a standardized regime of two antihypertensive medications to minimize drug interference; and (iv) RDN might be more effective in East Asian patients with higher salt intake and higher salt sensitivity. Further studies are required defining the effects of sodium and volume status on the response to RDN in Chinese patients—a racial difference in RDN response cannot be excluded. Acknowledgements Y.L. drafted the manuscript. All listed authors either participated in the study design and patient data collection or contributed to the writing of the first draft of the manuscript. Tigermed Consulting Ltd performed the statistical analysis and contributed to the writing of the study report. All authors were involved in interpretation of the data. All authors agreed on the content of the manuscript, reviewed drafts, and approved the final version. The trial was sponsored by Shanghai Golden Leaf MedTech Co. Ltd and was designed in collaboration with the steering committee and sponsor. The manuscript was written by the lead author with significant contributions from the trial's executive committee and all co-authors. The funder assisted with figure and table generation, copy editing, and formatting. We thank DRW Limited for editorial assistance, Dr Felix Mahfoud for expert review of the manuscript, all of the investigators for contributions to trial design, and Tigermed Consulting Ltd for clinical trial oversight and statistical analysis.
测试京东医生
主任医师
北京大学医院
16
人阅读
查看详情
文章 肌酸激酶788高，可能是肌源性疾病？
健康解码专家
1
人阅读
查看详情
文章 高血压病人能不能吃蛇莲消囊丸？
医疗趋势观察站
13
人阅读
查看详情
相关问诊
肺部手术后出现胸闷气喘，日常生活需要家人帮助，如何缓解这种情况？
就诊科室：呼吸内科
总交流次数：28
医生建议：根据你的症状和描述，可能是肺部手术后遗症引起的。建议你在家中使用制氧机进行吸氧治疗，并注意休息和营养的补充。同时，避免剧烈运动和重体力劳动，保持良好的心态也很重要。使用制氧机时需要注意保持周围环境的清洁和通风，避免火源和易燃物。另外，定期检查和维护制氧机也是必要的。
查看详情
老人家有冠心病和呼吸困难，走路超过一百米很吃力，想了解是否可以用制氧机长期治疗？
就诊科室：呼吸内科
总交流次数：15
医生建议：对于冠心病和呼吸困难的患者，需要定期复查和调整治疗方案。可以考虑使用扩张血管和改善心肺功能的药物来辅助治疗。同时，日常生活中要注意锻炼和饮食，避免过度劳累和刺激性食物。长期吸氧也是一种有效的居家治疗方法。
查看详情
老人家有肺气肿，想买一台家用制氧机，担心依赖性和选择合适的氧流量。
就诊科室：呼吸内科
总交流次数：17
医生建议：对于肺气肿患者，选择合适的制氧机非常重要。建议使用医用级别的3升制氧机，它可以提供稳定的氧气供应，帮助改善呼吸困难的症状。使用时，需要根据患者的具体情况调整氧流量，避免过高或过低的氧流量。同时，患者还需要注意日常生活中的防护措施，避免接触有害物质和环境污染，保持良好的生活习惯和饮食习惯，以延缓病情的进展。
查看详情
我有明显的胸闷和气喘症状，日常生活可以自理，能独立行走超过一百米，想知道是否可以使用制氧机来改善生活质量？
就诊科室：呼吸内科
总交流次数：30
医生建议：根据患者的症状和日常生活能力，建议使用医用级别的5升制氧机来辅助治疗慢性阻塞性肺病（COPD）。在使用制氧机时，请注意遵循产品说明书中的指导，避免不良反应的发生。日常使用时，建议将氧气流量控制在2或3档，必要时可以调到4档。同时，患者应注意保持良好的生活习惯，避免吸烟和接触有害气体，以减少对肺部的进一步损害。
查看详情
老年男性慢阻肺患者想在家中使用制氧机缓解呼吸困难，询问是否可以使用和注意事项。
就诊科室：呼吸内科
总交流次数：25
医生建议：对于慢阻肺患者，使用制氧机可以帮助缓解呼吸困难和其他相关症状。请确保按照医生的建议使用，并定期复诊以监测病情。同时，注意观察是否有任何不良反应或副作用出现。制氧机的流量和使用时长通常是可以调节的，具体的设置应该根据医生的建议和患者的实际需求来确定。请确保在使用制氧机时遵循医生的指导，并定期复诊以调整治疗方案。
查看详情
桂公网安备 45050202000590号 桂ICP备202200128号-5